Core Viewpoint - Fly-E Group, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between July 15, 2025, and August 14, 2025 [1][2]. Summary by Relevant Sections Class Action Details - The lawsuit claims that Fly-E provided overly positive statements while concealing material adverse facts about the safety of its lithium batteries, which adversely affected E-vehicle sales revenue [2]. - On August 14, 2025, Fly-E disclosed a 32% decrease in net revenues, primarily due to a drop in total units sold, linked to recent lithium-battery accidents involving E-Bikes and E-Scooters [2]. - Following this disclosure, Fly-E's stock price plummeted from $7.76 per share to $1.00 per share, marking an approximate 87% decline in just one day [2]. Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the company's revenue outlook and growth potential, particularly related to Pylarify's sales growth and market dynamics [2]. - It is alleged that Lantheus did not accurately understand the pricing and competitive dynamics of Pylarify's market, contrary to the optimistic reports provided by the company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fortinet, Inc. for alleged securities fraud affecting investors between November 8, 2024, and August 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Fortinet's management made false statements regarding the refresh cycle of their products, suggesting it would be more profitable than it actually was, as it involved old products that represented a "small percentage" of the Company's business [2]. - It is alleged that Fortinet misrepresented the number of FortiGate firewalls eligible for upgrades and that the refresh cycle was pushed through more quickly than communicated, with approximately half completed by the end of Q2 2025 [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case name Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - The James Hardie Industries plc is facing a class action lawsuit alleging securities fraud due to misleading statements about its North America Fiber Cement segment's performance during a period of inventory destocking [1][4][5]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc" and is filed in the Northern District of Illinois [1]. - Investors who purchased James Hardie common stock between May 20, 2025, and August 18, 2025, have until December 23, 2025, to seek lead plaintiff status [1][6]. - The lawsuit alleges that James Hardie executives made false assurances about the strength of their business segment despite evidence of declining sales and inventory issues [4][5]. Group 2: Allegations Against James Hardie - The lawsuit claims that starting in April and early May 2025, there was evidence of customer destocking, which was not disclosed to investors [4]. - On August 19, 2025, James Hardie reported a 12% decline in sales in the North America Fiber Cement segment, which led to a stock price drop of over 34% [5]. Group 3: Company Background - James Hardie Industries designs and manufactures a variety of fiber cement building products, with manufacturing facilities in the United States and Australia [3].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of federal securities laws due to false and misleading statements regarding the company's business and prospects [1][6]. Company Overview - MoonLake Immunotherapeutics is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology [4]. - The company's sole drug candidate, sonelokimab (SLK), is primarily developed for hidradenitis suppurativa (HS) and also targets psoriatic arthritis, psoriasis, and axial spondyloarthritis [4]. Clinical Development - MoonLake began its Phase 2b MIRA trial of sonelokimab in May 2022, reporting positive top-line results in June 2023, achieving its primary HiSCR75 endpoint [5]. - Follow-up data in October 2023 indicated further improvement with continued treatment, and both the FDA and EMA endorsed the proposed Phase 3 program, which began patient screening in May 2024 [5]. Allegations and Stock Impact - The lawsuit claims that throughout the class period, the defendants made false statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, including claims about molecular targets and clinical benefits [6]. - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to the traditional monoclonal structure BIMZELX, leading to a significant stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7].

Core Viewpoint - MoonLake Immunotherapeutics, a Swiss clinical-stage biotechnology company, is facing a class action lawsuit for allegedly misleading investors about the efficacy of its drug candidate SLK, which is aimed at treating inflammatory diseases driven by interleukin-17 (IL-17) [1][3]. Company Overview - MoonLake is focused on developing treatments for inflammatory diseases, particularly in dermatology and rheumatology, utilizing a unique Nanobody structure [1]. Legal Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information regarding the efficacy of SLK compared to BIMZELX, an FDA-approved drug. Key points include: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. - The distinct Nanobody structure of SLK does not provide a clinical benefit over the traditional monoclonal antibody structure of BIMZELX [3]. - Claims of increased tissue penetration by SLK do not translate to improved clinical efficacy [3]. - The company lacked a reasonable basis for its positive statements regarding SLK's superiority [3]. Stock Performance Impact - Following the announcement of disappointing week-16 results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against MoonLake. Those wishing to serve as lead plaintiffs must submit their papers by December 15, 2025 [5]. Legal Representation - Robbins LLP is leading the class action, specializing in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Baxter International, Inc. for misleading investors regarding the safety and operational issues of its Novum IQ Large Volume Pump, leading to significant financial losses for shareholders [1][5]. Summary by Sections Lawsuit Announcement - Glancy Prongay & Murray LLP has announced a class action lawsuit on behalf of Baxter investors who purchased shares between February 23, 2022, and July 30, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. Safety Issues and Stock Impact - Reports surfaced on April 7, 2025, regarding serious safety issues with Baxter's Novum LVP, leading to its removal from a hospital system due to claims that the pumps were unsafe [2]. - Baxter issued warning letters about underinfusion risks on April 24, 2025, and later revealed 79 reports of serious injuries and two patient deaths related to the device, prompting a Class I recall from the FDA [3]. - Following the announcement of a pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price dropped by $6.24, or 22.4%, closing at $21.61 per share [4]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [5][6]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and the risk of halting new sales of the Novum LVP due to safety concerns [5][6].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics ("MoonLake†or the "Company†) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the "Class Period†). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion. IF YOU SUFFER. ...

Core Viewpoint - A securities fraud class action lawsuit has been initiated against MoonLake Immunotherapeutics, alleging misrepresentations regarding its drug candidate sonelokimab [3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [3]. Group 2: Company Information - MoonLake's sole drug candidate, sonelokimab, was promoted as superior to competing monoclonal antibody drugs, which is central to the allegations in the lawsuit [4]. - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, which allows them to represent the class in the litigation [5]. Group 3: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless there is a recovery [5][6]. - The firm has a history of recovering over $3.5 billion for clients and has been recognized multiple times for its litigation success [6].